Covering the chain
Customers want us to keep control of any potential issues that can arise from the molecule – this demand comes from them and it has sometimes been a surprise when the molecule is already known.
As pipelines expand and outsourcing manufacturing activity continues to increase, demand within the pharmaceutical industry is thriving.
Pharmaceutical developers are partnering with contract development and manufacturing organisations (CDMOs) to strengthen their core capabilities in a bid to access to new technologies they do not possess in-house. This, paired with a surge in personalised therapies and more complex molecules entering the drug pipeline is causing more of the drug manufacturing process to be undertaken by contract service organisations as they strive to ensure they continue to meet the evolving needs of customers.
Gianluca Franguelli, Vice President of Corporate Development, at Recipharm discusses Recipharm’s business success in 2019 as well as the demand for repurposed existing molecules for niche applications via process redesign. He also sheds light on business unit growth following the trend towards integration in early chemistry.
For the full article see here.